Rising Global Burden of Infectious Diseases
The growing global impact of infectious diseases is a major factor fueling the nucleic acid amplification testing (NAAT) market. According to a 2024 study published in The Lancet, infectious diseases were responsible for 704 million disability-adjusted life years (DALYs) in 2019—accounting for 28% of all DALYs across 204 countries. Diseases such as tuberculosis, malaria, and HIV contributed significantly to this burden. Additionally, data from the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota emphasized that 85 specific pathogens were behind these numbers, underscoring the widespread threat of infectious diseases globally. The frequent emergence of new pathogens, such as novel coronaviruses, and the reappearance of older diseases highlight the urgent need for rapid, accurate diagnostic tools. NAAT provides exceptional sensitivity and specificity, even at low pathogen levels, making it indispensable for early detection, timely treatment, and outbreak control. This escalating need for accurate diagnostics is driving robust growth in the nucleic acid amplification testing market.

Growing Prevalence of Genetic Disorders
Another key growth driver for the NAAT market is the increasing recognition and diagnosis of genetic disorders. The World Health Organization (WHO) reports that congenital disorders cause approximately 240,000 newborn deaths annually and are responsible for another 170,000 deaths in children aged 1 month to 5 years. Though individual genetic conditions may be rare, collectively, they affect a significant global population. According to GeneHome, single-gene disorders affect an estimated 10 out of every 1,000 people worldwide. NAAT plays a critical role in diagnosing such disorders, including inherited conditions, chromosomal anomalies, and genetic predispositions to certain diseases. Its high accuracy in detecting specific genetic mutations makes NAAT increasingly vital for genetic screening, carrier testing, prenatal diagnosis, and personalized medicine. This widespread application continues to expand market demand for nucleic acid amplification testing.